Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys
PR Newswire - Mon Apr 14, 7:16AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN, MDVN, MSTX and ATHX can be downloaded upon signing up at:
Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease
PR Newswire - Mon Apr 14, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in an ex vivo study conducted at Loyola University Medical Center, MST-188 reduced the mean erythrocyte sedimentation rate (ESR) by 50% relative to control in blood collected from individuals with sickle cell disease. ESR, a common laboratory test and measure of inflammation, describes the rate at which red blood cells (RBC) travel through anti-coagulated blood. When an inflammatory process is present, the high proportion of proteins in the blood, such as fibrinogen, cause RBC to form aggregates, increasing viscosity and impairing microvascular blood flow. Data from the study were presented at the 8th Annual Sickle Cell Disease Research & Educational Symposium, currently underway in Miami.
A Small-Cap Biotech Stock With Promise: MSTX
at The Street - Wed Mar 26, 1:55PM CDT
This small-cap biotech stock could be setting up for a great buying opportunity here following the massive selloff in the space.
Mast Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Wed Mar 26, 7:15AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013.
Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
PR Newswire - Wed Mar 26, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia. Acute limb ischemia (ALI), an acute complication of peripheral arterial disease, describes a sudden decrease in perfusion of a limb, typically in the legs, that often threatens viability of the limb. Patients presenting with ALI have a poor short-term outlook, with 30-day amputation rates as high as 30% and a mortality rate around 15%. MST-188 for the treatment of ALI has been granted orphan drug designation by the U.S. Food and Drug Administration.
Active Stocks Coverage -- Research on Starbucks, Gerdau, Mast Therapeutics and Cia de Saneamento Basico do Estado
PR Newswire - Fri Mar 21, 9:28AM CDT
The trading session on Thursday, March 20, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based with 9 of 10 sectors ended the session in positive. Investor-Edge looks at some of the equities which traded the most shares during the session. These include FullStarbucks Corp. (NASDAQ: SBUX), Gerdau S.A. (NYSE: GGB), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Cia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS). Free technical research on SBUX, GGB, MSTX and SBS can be downloaded upon signing up at:
Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council
PR Newswire - Tue Mar 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug products containing non-purified poloxamers should not be substituted for MST-188 and that confusion between the two could have serious toxicity consequences.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 06, 12:39PM CST
These under-$10 stocks look ready to trade higher from current levels.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"
Mast Therapeutics acquires Aires Pharmaceuticals in all-stock transaction
M2 - Fri Feb 28, 3:43AM CST
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) disclosed on Thursday the completion of the acquisition of Aires Pharmaceuticals in an all-stock transaction.
Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
PR Newswire - Thu Feb 27, 1:18PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension.
Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd
PR Newswire - Tue Feb 25, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Cowen & Co. 34th Annual Healthcare Conference on Monday, March 3, 2014 at 4:50 p.m. Eastern time at The Boston Marriott Copley Place Hotel in Boston.
Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188
PR Newswire - Mon Feb 24, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, consistent with its prior guidance, it has initiated international enrollment in EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, with clinical sites now open in multiple foreign jurisdictions with high rates of hospitalization for sickle cell disease. The Company previously reported that it had met its goal of having 40 U.S. sites open by the end of 2013 and is on-track to opening an additional 30 sites outside of the U.S. by the end of 2014.
Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study
PR Newswire - Tue Feb 18, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 (low dose and high dose) in a model of chronic heart failure.
Mast Therapeutics to acquire Aires Pharmaceuticals
M2 - Tue Feb 11, 6:52AM CST
US-based biopharmaceutical company Mast Therapeutics Inc (NYSE MKT:MSTX) said on Monday that it has signed a definitive agreement to acquire Aires Pharmaceuticals Inc in exchange for Mast's common stock in an all-stock transaction.
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.
PR Newswire - Mon Feb 10, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.
Vista Partners Publishes February 2014 Macroeconomic & Investment Newsletter
Marketwire - Wed Feb 05, 8:01AM CST
Vista Partners ("Vista"
Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
PR Newswire - Wed Jan 08, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided an update on the status of EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease. Consistent with prior guidance, the Company announced that 40 clinical sites were opened in the U.S. by year-end 2013. In addition, clinical sites are expected to open in at least three countries outside the U.S. in the first quarter of 2014, leading to a total of approximately 30 ex-U.S. sites open by the end of 2014. Overall study enrollment is consistent with internal projections and the Company affirmed prior guidance that it expects to complete full enrollment for the trial by the end of 2015.
Mast Therapeutics To Present At The OneMedForum Emerging Company Finance Conference On January 14
PR Newswire - Tue Jan 07, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the OneMedForum Emerging Company Finance Conference on Tuesday, January 14th, 2014 at 2:10 p.m. Pacific time at The Westin Hotel in San Francisco.